Immune responses in age-related macular degeneration and a possible long-term therapeutic strategy for prevention
- PMID: 24709810
- PMCID: PMC4058353
- DOI: 10.1016/j.ajo.2014.03.014
Immune responses in age-related macular degeneration and a possible long-term therapeutic strategy for prevention
Abstract
Purpose: To describe the immune alterations associated with age-related macular degeneration (AMD); and, based on these findings, to offer an approach to possibly prevent the expression of late disease.
Design: Perspective.
Methods: Review of the existing literature dealing with epidemiology, models, and immunologic findings in patients.
Results: Significant genetic associations have been identified and reported, but environmentally induced (including epigenetic) changes are also an important consideration. Immune alterations include a strong interleukin 17 family signature as well as marked expression of these molecules in the eye. Oxidative stress as well as other homeostatic altering mechanisms occur throughout life. With this immune dysregulation there is a rationale for considering immunotherapy. Indeed, immunotherapy has been shown to affect the late stages of AMD.
Conclusion: Immune dysregulation appears to be an underlying alteration in AMD, as in other diseases thought to be degenerative and attributable to aging. Para-inflammation and immunosenescence may importantly contribute to the development of disease. The role of complement factor H still needs to be better defined, but in light of its association with ocular inflammatory conditions such as sarcoidosis, it does not appear to be unique to AMD but rather may be a marker for retinal pigment epithelium function. With the strong interleukin 17 family signature and the need to treat early on in the disease process, oral tolerance may be considered to prevent disease progression.
Published by Elsevier Inc.
Figures


Similar articles
-
Doyne lecture 2016: intraocular health and the many faces of inflammation.Eye (Lond). 2017 Jan;31(1):87-96. doi: 10.1038/eye.2016.177. Epub 2016 Sep 16. Eye (Lond). 2017. PMID: 27636226 Free PMC article. Review.
-
Age-related macular degeneration and the immune response: implications for therapy.Am J Ophthalmol. 2007 Oct;144(4):618-26. doi: 10.1016/j.ajo.2007.06.025. Epub 2007 Aug 15. Am J Ophthalmol. 2007. PMID: 17698021 Free PMC article. Review.
-
An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration.Prog Retin Eye Res. 2001 Nov;20(6):705-32. doi: 10.1016/s1350-9462(01)00010-6. Prog Retin Eye Res. 2001. PMID: 11587915 Review.
-
Oxidative stress, innate immunity, and age-related macular degeneration.AIMS Mol Sci. 2016;3(2):196-221. doi: 10.3934/molsci.2016.2.196. Epub 2016 May 11. AIMS Mol Sci. 2016. PMID: 27239555 Free PMC article.
-
A Perspective of AMD Through the Eyes of Immunology.Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD83-AMD92. doi: 10.1167/iovs.18-23893. Invest Ophthalmol Vis Sci. 2018. PMID: 30025105 Review.
Cited by
-
Allogenic iPSC-derived RPE cell transplants induce immune response in pigs: a pilot study.Sci Rep. 2015 Jul 3;5:11791. doi: 10.1038/srep11791. Sci Rep. 2015. PMID: 26138532 Free PMC article.
-
Interlink between Inflammation and Oxidative Stress in Age-Related Macular Degeneration: Role of Complement Factor H.Biomedicines. 2021 Jun 30;9(7):763. doi: 10.3390/biomedicines9070763. Biomedicines. 2021. PMID: 34209418 Free PMC article. Review.
-
Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study.J Ophthalmol. 2018 Jul 29;2018:5612342. doi: 10.1155/2018/5612342. eCollection 2018. J Ophthalmol. 2018. PMID: 30151278 Free PMC article.
-
Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye.Trends Mol Med. 2015 Jan;21(1):43-51. doi: 10.1016/j.molmed.2014.10.005. Epub 2014 Nov 1. Trends Mol Med. 2015. PMID: 25457617 Free PMC article. Review.
-
Potential participation of CTRP6, a complement regulator, in the pathology of age related macular degeneration.Jpn J Ophthalmol. 2022 May;66(3):326-334. doi: 10.1007/s10384-022-00913-4. Epub 2022 Apr 9. Jpn J Ophthalmol. 2022. PMID: 35397057
References
-
- United Nations. World Population Prospects: the 2000 Review. 2001 http://www.un.org/esa/population/publications/wpp2000/highlights.pdf. Published February 28, 2001.
-
- World Health Organization. Prevention of Blindness and Visual Impairment. [Accessed September 26, 2013];Priority Eye Diseases. 2012 http://www.who.int/blindness/causes/priority/en/index8.html.
-
- Congdon N, O’Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):477–485. - PubMed
-
- Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004 Apr;122(4):564–572. - PubMed
-
- Penfold PLKM, Sarks SH. Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol. 1985;223:69–76. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical